Harvard
Bomholt, T, Idorn, T, Knop, FK, Jørgensen, MB, Ranjan, AG, Resuli, M, Hansen, PM, Borg, R
, Persson, F, Feldt-Rasmussen, B & Hornum, M 2021, '
The Glycemic Effect of Liraglutide Evaluated by Continuous Glucose Monitoring in Persons with Type 2 Diabetes Receiving Dialysis'
Nephron, bind 145, nr. 1, s. 27-34.
https://doi.org/10.1159/000510613
APA
Bomholt, T., Idorn, T., Knop, F. K., Jørgensen, M. B., Ranjan, A. G., Resuli, M., ... Hornum, M. (2021).
The Glycemic Effect of Liraglutide Evaluated by Continuous Glucose Monitoring in Persons with Type 2 Diabetes Receiving Dialysis.
Nephron,
145(1), 27-34.
https://doi.org/10.1159/000510613
CBE
Bomholt T, Idorn T, Knop FK, Jørgensen MB, Ranjan AG, Resuli M, Hansen PM, Borg R
, Persson F, Feldt-Rasmussen B, Hornum M. 2021.
The Glycemic Effect of Liraglutide Evaluated by Continuous Glucose Monitoring in Persons with Type 2 Diabetes Receiving Dialysis.
Nephron. 145(1):27-34.
https://doi.org/10.1159/000510613
MLA
Vancouver
Author
Bomholt, Tobias ; Idorn, Thomas ; Knop, Filip K ; Jørgensen, Morten B ; Ranjan, Ajenthen G ; Resuli, Marsela ; Hansen, Pernille M ; Borg, Rikke
; Persson, Frederik ; Feldt-Rasmussen, Bo ; Hornum, Mads. /
The Glycemic Effect of Liraglutide Evaluated by Continuous Glucose Monitoring in Persons with Type 2 Diabetes Receiving Dialysis. I:
Nephron. 2021 ; Bind 145, Nr. 1. s. 27-34.
Bibtex
@article{901ddc57ef2a4e17b7d584df78c3d42f,
title = "The Glycemic Effect of Liraglutide Evaluated by Continuous Glucose Monitoring in Persons with Type 2 Diabetes Receiving Dialysis",
abstract = "AIMS: The aim of this study was to evaluate the effect of liraglutide treatment on glucose variability and the risk of hypoglycemia by continuous glucose monitoring (CGM) in persons with type 2 diabetes (T2D) and dialysis-dependent end-stage renal disease (ESRD).MATERIALS AND METHODS: We assessed CGM data from a previous trial where 24 persons with T2D and dialysis-dependent ESRD were allocated (1:1) to 12 weeks of double-blinded treatment with liraglutide (titrated to maximum tolerable dose up to 1.8 mg) or placebo as an add-on to preexisting antidiabetic treatment. CGM (Ipro2{\circledR}; Medtronic) was performed for up to 7 days at baseline and at weeks 2, 6, and 10. A linear mixed model was used to compare the 2 study arms.RESULTS: A CGM was worn at baseline by 12 persons in the liraglutide group and 10 in the placebo group (7 and 9 completed week 10, respectively). Glycated hemoglobin A1c (p = 0.81) and glucose variability was similar between the groups (standard deviation, p = 0.33; coefficient of variation, p = 0.16). Comparing baseline and week 10, the number of hypoglycemic events (glucose values between <3.9 and 3.0 mmol/L) increased in the liraglutide group compared with the placebo group (p = 0.02). The occurrence of hypoglycemic events below 3.0 mmol/L was similar between the groups (p = 0.36).CONCLUSIONS: In the present cohort of persons with T2D and dialysis-dependent ESRD, liraglutide treatment increased the risk of hypoglycemic events as compared to placebo (no difference was found for hypoglycemic events below 3.0 mmol/L). The majority of participants were co-treated with insulin.",
author = "Tobias Bomholt and Thomas Idorn and Knop, {Filip K} and J{\o}rgensen, {Morten B} and Ranjan, {Ajenthen G} and Marsela Resuli and Hansen, {Pernille M} and Rikke Borg and Frederik Persson and Bo Feldt-Rasmussen and Mads Hornum",
note = "{\circledC} 2020 S. Karger AG, Basel.",
year = "2021",
doi = "10.1159/000510613",
language = "English",
volume = "145",
pages = "27--34",
journal = "Experimental Nephrology",
issn = "0028-2766",
publisher = "S./Karger AG",
number = "1",
}
RIS
TY - JOUR
T1 - The Glycemic Effect of Liraglutide Evaluated by Continuous Glucose Monitoring in Persons with Type 2 Diabetes Receiving Dialysis
AU - Bomholt, Tobias
AU - Idorn, Thomas
AU - Knop, Filip K
AU - Jørgensen, Morten B
AU - Ranjan, Ajenthen G
AU - Resuli, Marsela
AU - Hansen, Pernille M
AU - Borg, Rikke
AU - Persson, Frederik
AU - Feldt-Rasmussen, Bo
AU - Hornum, Mads
N1 - © 2020 S. Karger AG, Basel.
PY - 2021
Y1 - 2021
N2 - AIMS: The aim of this study was to evaluate the effect of liraglutide treatment on glucose variability and the risk of hypoglycemia by continuous glucose monitoring (CGM) in persons with type 2 diabetes (T2D) and dialysis-dependent end-stage renal disease (ESRD).MATERIALS AND METHODS: We assessed CGM data from a previous trial where 24 persons with T2D and dialysis-dependent ESRD were allocated (1:1) to 12 weeks of double-blinded treatment with liraglutide (titrated to maximum tolerable dose up to 1.8 mg) or placebo as an add-on to preexisting antidiabetic treatment. CGM (Ipro2®; Medtronic) was performed for up to 7 days at baseline and at weeks 2, 6, and 10. A linear mixed model was used to compare the 2 study arms.RESULTS: A CGM was worn at baseline by 12 persons in the liraglutide group and 10 in the placebo group (7 and 9 completed week 10, respectively). Glycated hemoglobin A1c (p = 0.81) and glucose variability was similar between the groups (standard deviation, p = 0.33; coefficient of variation, p = 0.16). Comparing baseline and week 10, the number of hypoglycemic events (glucose values between <3.9 and 3.0 mmol/L) increased in the liraglutide group compared with the placebo group (p = 0.02). The occurrence of hypoglycemic events below 3.0 mmol/L was similar between the groups (p = 0.36).CONCLUSIONS: In the present cohort of persons with T2D and dialysis-dependent ESRD, liraglutide treatment increased the risk of hypoglycemic events as compared to placebo (no difference was found for hypoglycemic events below 3.0 mmol/L). The majority of participants were co-treated with insulin.
AB - AIMS: The aim of this study was to evaluate the effect of liraglutide treatment on glucose variability and the risk of hypoglycemia by continuous glucose monitoring (CGM) in persons with type 2 diabetes (T2D) and dialysis-dependent end-stage renal disease (ESRD).MATERIALS AND METHODS: We assessed CGM data from a previous trial where 24 persons with T2D and dialysis-dependent ESRD were allocated (1:1) to 12 weeks of double-blinded treatment with liraglutide (titrated to maximum tolerable dose up to 1.8 mg) or placebo as an add-on to preexisting antidiabetic treatment. CGM (Ipro2®; Medtronic) was performed for up to 7 days at baseline and at weeks 2, 6, and 10. A linear mixed model was used to compare the 2 study arms.RESULTS: A CGM was worn at baseline by 12 persons in the liraglutide group and 10 in the placebo group (7 and 9 completed week 10, respectively). Glycated hemoglobin A1c (p = 0.81) and glucose variability was similar between the groups (standard deviation, p = 0.33; coefficient of variation, p = 0.16). Comparing baseline and week 10, the number of hypoglycemic events (glucose values between <3.9 and 3.0 mmol/L) increased in the liraglutide group compared with the placebo group (p = 0.02). The occurrence of hypoglycemic events below 3.0 mmol/L was similar between the groups (p = 0.36).CONCLUSIONS: In the present cohort of persons with T2D and dialysis-dependent ESRD, liraglutide treatment increased the risk of hypoglycemic events as compared to placebo (no difference was found for hypoglycemic events below 3.0 mmol/L). The majority of participants were co-treated with insulin.
U2 - 10.1159/000510613
DO - 10.1159/000510613
M3 - Journal article
VL - 145
SP - 27
EP - 34
JO - Experimental Nephrology
JF - Experimental Nephrology
SN - 0028-2766
IS - 1
ER -